Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 4/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 6/20 | 0.36 |
| ▸ | TDO2 | P48775 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | TYK2 | P29597 | 2/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18714303 | 0.80 | METAP2 (0.58) | METAP2TRPA1CYP1A2IDO1TDO2 | |
| SCHEMBL30856325 | 0.79 | METAP2 (0.49) | METAP2TRPA1CYP1A2IDO1TDO2 | |
| SCHEMBL15808384 | 0.79 | METAP2 (0.49) | METAP2TRPA1CYP1A2IDO1TDO2 | |
| SCHEMBL14723220 | 0.79 | METAP2 (0.49) | METAP2TRPA1CYP1A2IDO1TDO2 | |
| SCHEMBL459141 | 0.79 | IDO1 (0.56) | METAP2TRPA1IDO1TDO2 | |
| SCHEMBL28850763 | 0.75 | ESR1 (0.42) | METAP2ESR1IDO1TDO2FGFR1 | |
| SCHEMBL21267264 | 0.75 | METAP2 (0.52) | METAP2TRPA1CYP1A2IDO1TDO2 | |
| SCHEMBL24045193 | 0.72 | TDO2 (0.47) | METAP2TRPA1IDO1TDO2 | |
| SCHEMBL19475693 | 0.72 | METAP2 (0.38) | METAP2TRPA1CYP1A2IDO1TDO2 | |
| SCHEMBL12683697 | 0.72 | FGFR1 (0.44) | METAP2CYP1A2IDO1TDO2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2019-11-21 | — | — | US | disclosed |
| WO-2018092047-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, ABL1, CNKSR1 | METAP2 4770/4885ESR1 2235/4885ESR2 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.